|Description||Zopolrestat is an inhibitor of Aldose Reductase(AR). It has been shown to play roles in inflammation and cancer. It is used for the treatment of diabetic nephropathy and cardiac disease. It was developed by Pfizer and was terminated in clinic phase 2 trials.|
|B0084-358923||25 mg||$198||In stock|
|B0084-358923||50 mg||$298||In stock|
|Appearance||Off white to light brown powder|
|Synonyms||3-[(5-Trifluoromethyl-2-benzothiazolyl)methyl]-3,4-dihydro-4-oxophthalazine-1-acetic acid;CP-73850;3,4-Dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic acid;Alond;Xedia;2-[4-Oxo-3-[[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl]phthalazin-1-yl]acetic acid;CP 73850; CP73850; CP-73850; Zopolrestat; Zopolrestatum|
|Solubility||DMSO: ≥20 mg/mL|
|Application||Zopolrestat is used for the treatment of diabetic nephropathy and cardiac disease.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Quantity||Grams to Kilograms|
|Boiling Point||598.7±60.0 °C | Condition: Press: 760 Torr|
|Melting Point||197-198 °C|
|Density||1.58±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
|Current Developer||Zopolrestat was developed by Pfizer and was terminated in clinic phase 2 trials.|
Alrestatin is an inhibitor of aldose reductase (IC50 = 148 μM).
Zenarestat is an aldose reductase inhibitor. It was investigated as a treatment of diabetic neuropathy and cataract. It was developed by Fujisawa Pharmaceutical...
Zopolrestat is an inhibitor of Aldose Reductase(AR). It has been shown to play roles in inflammation and cancer. It is used for the treatment of diabetic nephro...
Aldose reductase-IN-1, an aldose reductase inhibitor, could have potential biological usage in the study of breast cancer. IC50: 28.9 pM.
Alrestatin sodium is a specific inhibitor of aldose reductase (IC50 = 148 μM).
FR-62765, a derivative of WF-3681, is a novel aldose reductase inhibitor. It might be a useful drug for diabetic neuropathy.
Raniestat, a highly potent aldose reductase inhibitor currently under phase III clinical trials in the US and Canada, is used to treat diabetic neuropathies.
Isoliquiritigenin, an anti-tumor flavonoid from the root of Glycyrrhiza glabra, inhibiting aldose reductase with an IC50 of 320 nM.